Previous editions of EJC News Focus
- November 2011
Gordon Mills assesses the challenges we face in developing personalised medicine. - October 2011
Richard Sullivan explains why the spiralling rise in healthcare costs associated with cancer is unsustainable. - September 2011
Anne-Lise Borresen-Dale discusses key themes to emerge at the European Multidisciplinary Cancer Congress in Stockholm. - August 2011
Jean-Charles Soria, EJC's Drug Development Editor, on the need for a new consensus on assessing toxicities. - July 2011
EJC editor-in-chief Alexander Eggermont on recent advances in melanoma treatment. - June 2011
Jean-Yves Blay discusses how EORTC is adapting to the new environment for research. - April/May 2011
Cora Sternberg reveals exciting developments in the treatment of prostate cancer. - March 2011
EJC's editor for gastrointestinal cancers, Eric van Cutsem, discusses the disappointing findings of recent trials of bevacizumab in colon cancer - February 2011
Michel Coleman from the London School of Hygiene and Tropical Medicine discusses a comparison of cancer survival rates in different countries. - January 2011
Jan Willem Coebergh discusses a paper relating to the NELSON lung cancer trial.
EJC News Focus – December 2011
Loading EJC News Focus video
Manuela Schmidinger (Vienna, Austria), says that improved understanding of the molecular background of renal cell cancer has led to a flurry of new agents and, indeed, a paradigm shift in treatment. She discusses the new options clinicians have and the tools available for helping them decide which to use.